Skip to main content

Table 1 Baseline characteristics of the study population

From: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab

Variable   Value
Agea Mean ± SD 81.8 ± 7.9 (64 to 96)
Sexb Male 18 (37.5%)
  Female 30 (62.5%)
Eyeb OD 25 (47.2%)
  OS 28 (52.8%)
Lateralityb Unilateral 43 (89.6%)
  Bilateral 5 (10.4%)
DMb Nondiabetic 40 (83.3%)
  Diabetic 8 (16.7%)
Phakic statusb Pseudophakic 37 (69.8%)
  Phakic 16 (30.2%)
Legacyb L-Bevacizumab 10 (19.2%)
  L-Ranibizumab 42 (80.8%)
  1. OD right eye, OS left eye, DM diabetes mellitus, L-Bevacizumab Legacy-Bevacizumab, L-Ranibizumab Legacy-Ranibizumab
  2. aMean ± SD
  3. bNumber (percentage)
\